CCN2 and plasma cell myeloma: MiR-26b has been shown to be able to suppress the proliferation of human multiple myeloma cells via targeting a number of candidate genes including CTGF [39]; Meanwhile, Yang et al demonstrated in their study about human breast cancer that miR-26b inhibited breast cancer progression through modulating Fra-1 proto-oncogene [27].